Urol. praxi. 2024;25(3):110-113 | DOI: 10.36290/uro.2024.055

Metabolic risk factors or renal cell carcinoma

doc. MUDr. Michal Fedorko, Ph.D., FEBU
Urologická klinika FN Brno
Lékařská fakulta MU Brno

Renal cell carcinoma is common in developed countries in Europe and North America. These regions are characterized by high income and the so-called "western" lifestyle which is associated with the occurrence of metabolic syndrome and its components. These have an impact not only on cardiovascular disease and diabetes, but also on the development of malignant tumours. Obesity and hypertension are typical risk factors for renal cell carcinoma. This review describes the relationship between known metabolic risk factors and renal cancer carcinogenesis, while also discussing possible preventive strategies to improve metabolic dysfunction and thus reduce the risk of (not only) renal cell carcinoma.

Keywords: diabetes, metabolic syndrome, obesity, renal cell carcinoma, risk factors.

Accepted: October 1, 2024; Published: November 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fedorko M. Metabolic risk factors or renal cell carcinoma. Urol. praxi. 2024;25(3):110-113. doi: 10.36290/uro.2024.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 14.11.2025

    References

    1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today (version 1) [online]. Lyon, France: International Agency for Research on Cancer. 2024. [cit. 12-3-2024]. Dostupné z: https://gco.iarc.who.int/today.
    2. Bukavina L, Bensalah K, Bray F, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022;82(5):529-542. Go to original source... Go to PubMed...
    3. Turner RM, Morgan TM, Jacobs BL. Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon. Urol Clin North Am. 2017;44(2):147-154. Go to original source... Go to PubMed...
    4. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, 2005. Verze 7.0 [2007], ISSN 1802-8861. [cit. 12-3-2024]. Dostupné z: http://www.svod.cz.
    5. Ondrušová M, Bujdák P. Epidemiológia zhubných nádorov obličky. In: Breza J a kol. Nádory obličiek. Bratislava: OG - Vydavateľstvo Poľana; 2008. p. 23-31.
    6. Wozniak M, Le Calvez-Kelm F, Abedi-Ardekani B, et al. Integrative Genome-Wide Gene Expression Profiling of Clear Cell Renal Cell Carcinoma in Czech Republic and in the United States. Plos One. 2013;8(3):e57886. Go to original source... Go to PubMed...
    7. Ljungberg B, Albiges L, Bedke J, et al. EAU Guidelines on Renal Cell Carcinoma. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023 ed. Arnhem, The Netherlands: EAU Guidelines Office; 2023. p. 1-100.
    8. Benichou J, Chow WH, McLaughlin JK, et al. Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol. 1998;148(5):424-430. Go to original source... Go to PubMed...
    9. Shebl FM, Warren JL, Eggers PW, et al. Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012;13:65. Go to original source... Go to PubMed...
    10. Tahbaz R, Schmid M, Merseburger AS. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol. 2018;28(1):62-79. Go to original source... Go to PubMed...
    11. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. Go to original source... Go to PubMed...
    12. Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk. Curr Opin Urol. 2022;32(6): 594-597. Go to original source... Go to PubMed...
    13. Bulut S, Aktas BK, Erkmen AE, et al. Metabolic syndrome prevalence in renal cell cancer patients. Asian Pac J Cancer Prev. 2014;15(18):7925-7928. Go to original source... Go to PubMed...
    14. Karra P, Winn M, Pauleck S, et al. Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome. Obesity. 2022;30(7):1323-1334. Go to original source... Go to PubMed...
    15. Dursun M, Besiroglu H, Otunctemur A, et al. Is Cardiometabolic Index a Predictive Marker for Renal Cell Cancer Aggressiveness? Prague Med Rep. 2019;120(1):10-17. Go to original source... Go to PubMed...
    16. Horiguchi A, Sumitomo M, Asakuma J, et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res. 2004;10(24):8648-8655. Go to original source... Go to PubMed...
    17. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer - Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. Go to original source... Go to PubMed...
    18. Liao LM, Hofmann JN, Cho E, et al. Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. Cancer Causes Control. 2017;28(7):801-807. Go to original source... Go to PubMed...
    19. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74-84. Go to original source... Go to PubMed...
    20. Solarek W, Koper M, Lewicki S, et al. Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. J Cell Commun Signal. 2019;13(3):381-394. Go to original source... Go to PubMed...
    21. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97-101. Go to original source... Go to PubMed...
    22. Kim LH, Doan P, He Y, et al. A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes. J Urol. 2021;205(2):346-355. Go to original source... Go to PubMed...
    23. Albiges L, Hakimi AA, Xie W, et al. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016;34(30):3655-63. Go to original source... Go to PubMed...
    24. Venkatesh N, Martini A, McQuade JL, et al. Obesity and renal cell carcinoma: Biological mechanisms and perspectives. Semin Cancer Biol. 2023;94:21-33. Go to original source... Go to PubMed...
    25. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219-234. Go to original source... Go to PubMed...
    26. Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer. 2013;108(4):798-811. Go to original source... Go to PubMed...
    27. Williams PT. Reduced risk of incident kidney cancer from walking and running. Med Sci Sports Exerc. 2014;46(2):312-317. Go to original source... Go to PubMed...
    28. Rysz J, Franczyk B, Ławiński J, et al. The Role of Metabolic Factors in Renal Cancers. Int J Mol Sci. 2020;21(19):7246. Go to original source... Go to PubMed...
    29. Nayan M, Punjani N, Juurlink DN, et al. Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2019;42(3):275-284. Go to original source... Go to PubMed...
    30. Hidayat K, Du X, Zou SY, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. Go to original source... Go to PubMed...
    31. Leiba A, Kark JD, Afek A, et al. Hypertension in adolescence is not an independent risk factor for renal cancer: a cohort study of 918,965 males. J Am Soc Hypertens. 2013;7(4):283-288. Go to original source... Go to PubMed...
    32. Chow WH, Gridley G, Fraumeni JF, et al. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305-1311. Go to original source... Go to PubMed...
    33. Xie Y, Xu P, Wang M, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging. 2020;12(2):1545-1562. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.